Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Sarclisa (isatuximab-irfc)
i
Other names:
SAR650984, SAR-650984, hu38SB19, UNII-R30772KCU0
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(11)
News
Trials
Company:
AbbVie, Sanofi
Drug class:
CD38 inhibitor
Related drugs:
‹
daratumumab (26)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
daratumumab (26)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
›
Associations
(11)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
isatuximab-irfc
Sensitive: A1 - Approval
isatuximab-irfc
Sensitive
:
A1
isatuximab-irfc
Sensitive: A1 - Approval
isatuximab-irfc
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: A1 - Approval
pomalidomide + isatuximab-irfc
Sensitive
:
A1
pomalidomide + isatuximab-irfc
Sensitive: A1 - Approval
pomalidomide + isatuximab-irfc
Sensitive
:
A1
Chr amplification(1)(q21)
Multiple Myeloma
Chr amplification(1)(q21)
Multiple Myeloma
pomalidomide + isatuximab-irfc
Sensitive: B - Late Trials
pomalidomide + isatuximab-irfc
Sensitive
:
B
pomalidomide + isatuximab-irfc
Sensitive: B - Late Trials
pomalidomide + isatuximab-irfc
Sensitive
:
B
Chr amplification(1)(q21)
Multiple Myeloma
Chr amplification(1)(q21)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
Chr t(4;14)
Multiple Myeloma
Chr t(4;14)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
PD-L1 expression
Lymphoma
PD-L1 expression
Lymphoma
cemiplimab-rwlc + isatuximab-irfc
Sensitive: C3 – Early Trials
cemiplimab-rwlc + isatuximab-irfc
Sensitive
:
C3
cemiplimab-rwlc + isatuximab-irfc
Sensitive: C3 – Early Trials
cemiplimab-rwlc + isatuximab-irfc
Sensitive
:
C3
CD38 positive
Multiple Myeloma
CD38 positive
Multiple Myeloma
isatuximab-irfc + K-NK004
Sensitive: D – Preclinical
isatuximab-irfc + K-NK004
Sensitive
:
D
isatuximab-irfc + K-NK004
Sensitive: D – Preclinical
isatuximab-irfc + K-NK004
Sensitive
:
D
CD38 expression
B Acute Lymphoblastic Leukemia
CD38 expression
B Acute Lymphoblastic Leukemia
isatuximab-irfc
Sensitive: D – Preclinical
isatuximab-irfc
Sensitive
:
D
isatuximab-irfc
Sensitive: D – Preclinical
isatuximab-irfc
Sensitive
:
D
CD38 expression
T Acute Lymphoblastic Leukemia
CD38 expression
T Acute Lymphoblastic Leukemia
isatuximab-irfc
Sensitive: D – Preclinical
isatuximab-irfc
Sensitive
:
D
isatuximab-irfc
Sensitive: D – Preclinical
isatuximab-irfc
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login